source
- Moderna’s melanoma vaccine trial success sparks $45 billion market value surgeModerna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…
- Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impactAs the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…Fierce Biotech · 10h ago↗ source